The statement points out that the clock is ticking for European climate and competitive ambitions. Europe should create a regulatory and market framework that enables long term investment in, and growth of, its scientific and company base. Urgent action is needed to mordernise GMO legislation, prove the value of industrial biotechnology to society, environment and economy and make investment into commercial scale up of novel bio-based technologies and processes within Europe a priority, for impactful performance in mainstream manufacturing.
The EFIB Vienna Declaration deserves a wider audience. Therefore, it will be relaunched on 30 November, to set the challenge for Europe and discuss what this means for policy, regulation, investment and innovation.
Claire Skentelbery, Director General, EuropaBio will present the EFIB Vienna Statement and moderate a panel discussion with:
- Simone Schmiedtbauer, Member of the European Parliament
- Stefan Buchholz, Head of R&D for the Division Nutrition & Care, Evonik
- Elke Duwenig, Senior Expert Global Regulatory / Public & Government Affairs Biotechnology, Nutrition & Health, BASF
- James Philp, Policy Analyst, Science and Technology Division, OECD.
Read the full Vienna Statement and participate in the discussion during the 12 months until the next EFIB conference in Vilnius, Lithuania (October 2022).
Image: Nok Lek/Shutterstock
